Drugs / GB261
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07159009 | Sep 2025 → Dec 2026 expected | systemic sclerosis | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06945068 | Jun 2025 overdue | systemic lupus erythematosus | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04923048 | Aug 2021 → Jun 2024 | B-cell chronic lymphocytic leukemia | Genor Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GB261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06945068 ↗ |
| Modality | Protein / enzyme biologic | “GB261 is a novel CD20/CD3 bispecific TCE” NCT06945068 ↗ |
| Route | Intravenous | “via IV infusion” NCT04923048 ↗ |